MA52973A - Formes solides de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azétidin-3-yl)amino)phényl)-3-méthyl-1,3,4,9-tétrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol et procédés pour la préparation de composés tricycliques condensés comprenant une fraction phényle ou pyridinyle substituée et leurs méthodes d'utilisation - Google Patents
Formes solides de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azétidin-3-yl)amino)phényl)-3-méthyl-1,3,4,9-tétrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol et procédés pour la préparation de composés tricycliques condensés comprenant une fraction phényle ou pyridinyle substituée et leurs méthodes d'utilisationInfo
- Publication number
- MA52973A MA52973A MA052973A MA52973A MA52973A MA 52973 A MA52973 A MA 52973A MA 052973 A MA052973 A MA 052973A MA 52973 A MA52973 A MA 52973A MA 52973 A MA52973 A MA 52973A
- Authority
- MA
- Morocco
- Prior art keywords
- phenyl
- difluoropropan
- fluoropropyl
- azetidin
- pyrido
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862687930P | 2018-06-21 | 2018-06-21 | |
PCT/US2019/037492 WO2019245974A1 (fr) | 2018-06-21 | 2019-06-17 | Formes solides de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azétidin-3-yl)amino)phényl)-3-méthyl-1,3,4,9-tétrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol et procédés pour la préparation de composés tricycliques condensés comprenant une fraction phényle ou pyridinyle substituée et leurs méthodes d'utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
MA52973A true MA52973A (fr) | 2021-04-28 |
MA52973B1 MA52973B1 (fr) | 2023-08-31 |
Family
ID=73543352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA52973A MA52973B1 (fr) | 2018-06-21 | 2019-06-17 | Formes solides du sel de tartrate de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azétidin-3-yl)amino)phényl)-3-méthyl-1,3,4,9-tétrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, procédé pour leur préparation et méthodes de leur utilisation pour le traitement de cancers |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR114974A1 (fr) |
MA (1) | MA52973B1 (fr) |
-
2019
- 2019-06-17 MA MA52973A patent/MA52973B1/fr unknown
- 2019-06-21 AR ARP190101721A patent/AR114974A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
MA52973B1 (fr) | 2023-08-31 |
AR114974A1 (es) | 2020-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL278063A (en) | Solid forms of 3-((R3,R1)-1-(6,2-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-9,4 3,1-tetrahydro-H2-pyrido[4,3-B]indol-2-yl]2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds containing a substituted phenyl or pyridinyl residue, including methods for using them | |
MA31764B1 (fr) | Composés et compositions en tant que modulateurs de l'activité de gpr119 | |
MA55022A (fr) | Compositions comprenant de la 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) pour une utilisation dans le traitement de troubles mentaux | |
MA52488B1 (fr) | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation | |
MA52492A (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
MA47043A1 (fr) | Composés indole carboxamides utiles comme inhibiteurs de kinase | |
MA51520A (fr) | Dérivés de 1,3,4,5-tétrahydro-2h-pyrido[4,3-b]indole pour le traitement, le soulagement ou la prévention de troubles associés à des agrégats de tau comme la maladie d'alzheimer | |
TNSN06187A1 (fr) | Arylpyrazoles substitues servant d'agents parasiticides | |
MA30906B1 (fr) | Composes et compositions en tant quinhibiteurs des proteines kinases | |
MA46101B1 (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
MA42397B1 (fr) | 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b | |
TNSN07258A1 (fr) | Derives de quinoleine heteroaromatiques et leur utilisation comme inhibiteurs de pde10 | |
SG11202102057SA (en) | Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate | |
MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif | |
JP2017214410A5 (fr) | ||
JP2009530282A5 (fr) | ||
MA43468B1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
DK2044067T3 (da) | Fremgangsmåde til fremstilling af 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octanbromid | |
MA28105A1 (fr) | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l'obesite | |
MA56114A (fr) | Composés pour le traitement de troubles dépendant de la kinase | |
MA52973A (fr) | Formes solides de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azétidin-3-yl)amino)phényl)-3-méthyl-1,3,4,9-tétrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol et procédés pour la préparation de composés tricycliques condensés comprenant une fraction phényle ou pyridinyle substituée et leurs méthodes d'utilisation | |
MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
MA38425A1 (fr) | Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 | |
NO20083756L (no) | Fremgangsmate for fremstilling av escitalopram | |
ZA200603048B (en) | 1-2'(1,4'-Biperidin-1'-yl)-1-(phenyl)ethylcyclohexanol derivatives as monoamine reuptake modulators for the treatment of visomotor symptoms |